Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry

Hormone Molecular Biology and Clinical Investigation

Volumn 23, Issue 3, 2015, Pages 79-84

  Trabert, Britton ^a   Falk, Roni T ^a   Stanczyk, Frank Z ^b   McGlynn, Katherine A ^a   Brinton, Louise A ^a   Xu, Xia ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

breast cancer risk; liquid chromatography tandem mass spectrometry; reproducibility; serum progesterone assay

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; 3ALPHA DIHYDROPROGESTERONE; 5ALPHA PREGNANE 3,20 DIONE; PREGNENOLONE; PROGESTERONE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HUMAN; LIMIT OF QUANTITATION; MALE; NORMAL HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; AGED; BLOOD; BREAST TUMOR; LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZATION; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGESTERONE; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TANDEM MASS SPECTROMETRY;

EID: 84958752375     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2015-0026     Document Type: Article

References (22)

1. Endogenous hormones and breast cancer collaborative group, Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF, Brinton LA, Overvad K, Kaaks R, Trichopoulou A, Clavel-Chapelon F, Pani co S, Duell EJ, Peeters PH, Rinaldi S, Fentiman IS, Dowsett M, Manjer J, Lenner P, Hallmans G, Baglietto L, English DR, Giles GG, Hopper JL, Severi G, Morris HA, Hankinson SE, Tworoger SS, Koenig K, Zeleniuch-Jacquotte A, Arslan AA, Toniolo P, Shore RE, K r ogh V, Micheli A, Berrino F, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Lui LY, Cummings SR, Gunter MJ, Rohan TE, Strickler HD. Circulating sex hormones and breast cancer risk factors in postmenopaus al women: reanalysis of 13 studies. Br J Cancer 2011;105:709-22.
2. Endogenous hormones and breast cancer collaborative group, Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, Si eri S, Brinton LA, Dorgan JF, Dossus L, Dowsett M, Eliassen AH, Fortner RT, Hankinson SE, Helzlsouer KJ, Hoffman-Bolton J, Comstock GW, Kaaks R, Kahle LL, Muti P, Overvad K, Peeters PH, Riboli E, Rinaldi S, Rollison DE, Stanczyk FZ, Trichopoulos D, Tworog e r SS, Vineis P. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013;10:1009-19.
3. Endogenous hormones and prostate cancer collaborative group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100:170-83.
4. Black A, Pinsky PF, Grubb RL, Falk RT, Hsing AW, Chu L, Meyer T, Veenstra TD, Xu X, Yu K, Ziegler RG, Brinton LA, Hoover RN, Cook MB. Sex steroid hormone metabolism in relation to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2014;23:2374-82.
5. Brinton LA, Key TJ, Kolonel LN, Michels KB, Sesso HD, Ursin G, Van Den Eeden SK, Wood SN, Falk RT, Parisi D. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol 2015;33:2041-50.
6. Brinton LA, Richesson D, Leitzmann MF, Gierac h GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr. Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev 2008;17:3150-60.
7. Fournier A,Berrino F,Riboli E,Avenel E,Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort Intl J Cancer 2005 114 448-54
8. Fournier A, Berrino F, Riboli E, Avenel E, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Intl J Cancer 2005;114:448-54. 8. Collaborative group on the epidemiologic studies of ovarian cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-Analysis of 52 epidemiol ogical studies. Lancet 2015;385:1835-42.
9. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Park Y, Brinton LA. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2013;132:417-26.
10. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 2014;142:83-9.
11. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Acensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E, Women's hea lth initiative investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004.
12. Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ, Gapstur SM. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev 2009;18:2835-41.
13. Johnson JR, Lacey JV, DeAnn Lazovich D, Geller MA, Schairer C, Schatzkin A, Flood A. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:196-203.
14. Lange CA. Challenges to defining a role for progesterone in breast cancer. Steroids 2008;73:914-21.
15. Lange CA, Yee D. Progesterone and breast cancer. Womens Health 2008;4:151-62.
16. Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HT. Progesterone metabolites regulate induction, growth, and suppression of estrogen-And progesterone-receptor-negative human breast cell tumors. Breast Cancer Res 2013;15:R38.
17. Pawlak KJ, Zhang G, Wiebe JP. Membrane 5-Alpha-pregnane-3,20-dione (5-AlphaP) receptors in MCF-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5-AlphaP and down-regulated by the progesterone metabolites, 3-Alphadihydroprogesterone and 20-Alpha-dihydroprogesterone, with associated changes in cell proliferation and detachment. J Steroid Biochem Mol Biol 2005;97:278-88.
18. Pasqualini JR, Chetrite G. The a nti-Aromatase effect of progesterone and of its natural metabolites 20-Alpha-And 5-Alphadihydroprogesterone in the MCF-7-Aro breast cancer cell line. Anticancer Res 2008;28:2129-33.
19. Zhang Y, Nadeau M, Faucher F, Lescelleur O, Biron S, Daris M, Rheaume C, Luu-The V, Tchernof A. Progesterone metabolism in adipose cells. Mol Cell Endocrinol 2009;298:76-83.
20. Kinoshita T, Honma S, Shibata Y, Yamashita K, Watanabe Y, Maekubo H, Okuyama M, Takashima A, Takeshita N. An innovative LC-MS/MS-based method for determining CYP17 and CYP19 activity in the adipose tissue of pre-And postmenopausal and ovarie ctomized women using 13C-labeled steroid substrates. J Clin Endocrinol Metab 2014;99:1339-47.
21. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progestero ne concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65.
22. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Han kinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406-15.